Prospect

Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors

  1. Dianne C. Mitchell1,
  2. Brad A. Bryan PhD2,*

Article first published online: 12 JUL 2010

DOI: 10.1002/jcb.22764

Issue

Journal of Cellular Biochemistry

Journal of Cellular Biochemistry

Volume 111, Issue 3, pages 543–553, 15 October 2010

Additional Information

How to Cite

Mitchell, D. C. and Bryan, B. A. (2010), Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors. J. Cell. Biochem., 111: 543–553. doi: 10.1002/jcb.22764

Author Information

  1. 1

    Acceleron Pharmaceuticals, Cambridge, Massachusetts

  2. 2

    Ghosh Science and Technology Center, Department of Biology, Worcester State College, Worcester, Massachusetts

*Ghosh Science and Technology Center, Department of Biology, Worcester State College, Worcester, MA 01602.

Publication History

  1. Issue published online: 12 JUL 2010
  2. Article first published online: 12 JUL 2010
  3. Accepted manuscript online: 12 JUL 2010 12:00AM EST
  4. Manuscript Received: 24 JUN 2010
  5. Manuscript Accepted: 24 JUN 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (616K)

Keywords:

  • vascular endothelial growth factor;
  • Avastin;
  • angiogenesis

Abstract

Healthy cells, as well as benign and malignant tumors, depend upon the body's blood supply to bring in oxygen and nutrients and carry away waste products. Using this property against tumors, anti-angiogenic therapy targets the tumor vasculature with the aim of starving the tumor, and has demonstrated exceptional clinical efficacy against a number of tumors. This review discusses the current state of knowledge regarding anti-angiogenic therapies presently available to patients, and garners from both preclinical and clinical literature the benefits and side effects associated with anti-angiogenic therapies, the unfortunate mechanisms of acquired resistance to these novel therapeutics, and highlights promising next generation anti-angiogenics that may overcome the limitations encountered with first generation therapies. J. Cell. Biochem. 111: 543–553, 2010. © 2010 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (616K)